Infusion 51a's Press Releases
Our Portfolio Companies' Press Releases
His Excellency Ahmed Elmetwally exclusively invites Infusion 51a Executives to be part of the International Indo-Arab Conference in Medicine 2022
Dubai, UAE, November 27th, 2022 – Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle East this
Infusion 51a Executives attend the 10th Emirates Oncology Conference in Abu Dhabi, UAE
Abu Dhabi, UAE, November 26th, 2022 – Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle East
Infusion 51a Executives Participate in the 5th Annual Combined Gulf Cancer Conference in Sharjah, UAE
Sharjah, UAE, November 23rd, 2022 – Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle East this
Infusion 51a Executives attend two major events: the Formula 1 Race in Abu Dhabi and the DP World Tour Championship in Dubai
Abu Dhabi and Dubai, UAE. November 20th, 2022. Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle
Infusion 51a Executives attend the Abu Dhabi Finance Week 2022, a Highlight during their Middle East trip
From left to right: Infusion 51a’s General Partner, Mr. Scott VanderMeer, and Director of Strategic Growth in the MENA Region, Mr. Mehrab Ajalli Abu Dhabi,
Infusion 51a steps into Dubai attending the Healthcare Future Summit
Left to right: Ms. Sion Hau, Ms. Maryam Siddique, Dr. Louiza Chitour, Ms. Kawthar Bukhari, Mr. Scott VanderMeer and Mr. Mehrab Ajalli Dubai, UAE and
Our Portfolio Companies' Press Releases
Our Portfolio Companies' Press Releases
Theralink’s Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative
Golden, Colorado — January 17, 2023 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel quantitative protein and
Theralink® Technologies Appoints Michael Vallone as Senior Director of Commercialization
Mr. Vallone’s Appointment Supports the Company’s Shift from R&D to a Commercially Driven Enterprise GOLDEN, Colo., Jan. 9, 2023 /PRNewswire/ — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision oncology
Theralink® Technologies Appoints Seasoned Commercial Leader, Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology Company
Faith, a Seasoned Genomics Commercial Leader with a Special Interest in Reverse Phase Protein Array Technology and Biomarkers, will Lead Theralink’s Commercialization Strategy Golden, Colorado
Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium
Presented findings highlight the unique insights that Theralink’s Assay generates to advance breast cancer research and care Golden, Colorado — December 1, 2022 — Theralink
Theralink® Technologies Achieves the First College of American Pathologists Accreditation for a Commercial Reverse Phase Protein Array Laboratory in U.S.
College of American Pathologists (CAP) Accreditation Signifies the Highest Standards in Laboratory Practice Golden, Colorado — November 28, 2022 — Theralink Technologies (OTC: THER) (“Theralink”
Theralink® Technologies Receives Final Medicare Reimbursement Rate Determination and PTAN Enrollment
Important Milestone Toward Enabling Increased Access and Insight for Patients With Advanced Breast Cancer Through Theralink’s Precision Oncology Test Golden, Colorado — November 14, 2022